

Generic Name: Tepotinib

Therapeutic Class or Brand Name: Tepmetko®

Applicable Drugs (if Therapeutic Class): N/A

GPI Code: 21533073100320

Preferred: N/A

Non-preferred: N/A

Date of Origin: 3/8/2021

Date Last Reviewed / Revised: N/A

PRIOR AUTHORIZATION CRITERIA

(MAY BE CONSIDERED MEDICALLY NECESSARY WHEN CRITERIA I - IV ARE MET)

- I. Documented diagnosis of metastatic non-small cell lung cancer (NSCLC).
- II. Presence of mesenchymal epithelial transition (MET) exon 14 skipping alteration.
- III. Age \geq 18 years old.
- IV. Prescribed by or in consultation with an oncologist.

EXCLUSION CRITERIA

- N/A

OTHER CRITERIA

- Interstitial Lung Disease (ILD)/Pneumonitis: Immediately withhold Tepmetko in patients with suspected ILK/pneumonitis. Permanently discontinue Tepmetko in patients diagnosed with ILD/pneumonitis of any severity.
- Hepatotoxicity: Monitor liver function tests. Withhold, dose reduce, or permanently discontinue Tepmetko based on severity.
- Embryo-fetal toxicity: Tepmetko can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception.

QUANTITY / DAYS SUPPLY RESTRICTIONS

- 225 mg tablets: up to 60 tablets per 30 days.

APPROVAL LENGTH

- **Authorization**: 1 year.
- **Re-Authorization**: 1 year, an updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

APPENDIX

- N/A

REFERENCES

1. Tepmetko® (Tepotinib) [package insert]. Darmstadt, Germany: Merck KGaA, February 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf.
2. Medispan.
3. NCCN Guidelines Version 4.2021 – Non Small Cell Lung Cancer https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.